Evaluating amyloid burden in cardiac amyloidosis using bone scintigraphy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on improving the assessment of cardiac amyloidosis by utilizing quantitative analysis methods of bisphosphonate scintigraphy. It aims to provide a more accurate evaluation of amyloid burden and patient prognosis compared to traditional semi-quantitative methods. The study will involve patients diagnosed with transthyretin cardiac amyloidosis, and will assess the effectiveness of bone scintigraphy in monitoring disease progression over time. By enhancing diagnostic capabilities, the study seeks to contribute to better patient management and treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient, male or female, over 18 years of age
* Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy
* Patient with signed consent

Exclusion Criteria:

* Patients with systemic AL amyloidosis
* Protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision
* Pregnant or breastfeeding woman

Where it's running

• Hôpital privé Le Bois
  Lille, France Recruiting

Study contacts

• Principal investigator: Fredric MOUQUET — Hôpital Privé Le Bois
• Study coordinator: Frederic MOUQUET
• Email: fmouquet@ovh.fr
• Phone: 0642377375

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liver and Coagulation Markers in ATTR Cardiac Amyloidosis

  This study tests liver function and blood-clotting markers in people with ATTR-CA to see if they reflect disease severity and progression.

  Recruiting University of Messina · Messina, Sicily · NCT07766135

• Cardiac Amyloidosis: See if Intracardiac Thrombi are Common on CT

  This study tests whether a contrast-enhanced cardiac CT can reliably detect intracardiac thrombi in adults with cardiac amyloidosis.

  Recruiting Centre Hospitalier Universitaire Dijon · Dijon · NCT07648303

• Higher pacemaker rate for people with cardiac amyloidosis

  This study will see if temporarily increasing the pacemaker rate improves heart-failure symptoms and exercise tolerance in adults with cardiac amyloidosis who already have pacemakers.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07583823

• Using [64Cu]FBP8 PET/MR to find intracardiac blood clots in cardiac amyloidosis

  We'll test whether a [64Cu]FBP8 PET/MR scan can find blood clots inside the heart of people with cardiac amyloidosis who have atrial fibrillation or atrial flutter.

  Recruiting Phase 3 Brigham and Women's Hospital · Boston, Massachusetts · NCT07560306

• Chest pain screening for hidden cardiac amyloidosis

  We will test whether men over 65 who have chest pain but no coronary artery disease might have hidden cardiac amyloidosis using blood and urine tests, ECG and echocardiography, bone scintigraphy, and sometimes a heart biopsy.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT07435168

• Using advanced heart MRI to improve diagnosis and risk prediction for rare cardiomyopathies

  This project tests whether advanced cardiac MRI techniques can help diagnose and predict future risk for people with rare heart muscle diseases like Danon, Fabry, cardiac amyloidosis, Noonan syndrome, and cardiac sarcoidosis.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07336394

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.